logo
Plus   Neg
Share
Email

Cyclacel Pharmaceuticals Inc. (CYCC) Has Dropped To A New Low On Study Results

Cyclacel Pharmaceuticals Inc. (CYCC) announced Tuesday morning that the independent Data and Safety Monitoring Board of its Phase 3 SEAMLESS study of oral sapacitabine capsules, in acute myeloid leukemia, determined that it would be unlikely for the study to reach statistically significant improvement in survival.

Cyclacel Pharmaceuticals gapped open dramatically lower this morning and is now down 2.06 at $0.77 on the highest volume of the year. The stock has plunged to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT